Choose Your Country or Region

Carboplatin (NSC 241240)

Name: Carboplatin (NSC 241240)
Brand: Selleck Chemicals
SKU: S1215
Rating: 5 (82 reviews)

Catalog No.S1215 Synonyms: JM-8, CBDCA

For research use only.

Carboplatin (NSC 241240, JM-8, CBDCA) is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells. Solutions are best fresh-prepared.

Carboplatin (NSC 241240) Chemical Structure

CAS No. 41575-94-4

Selleck's Carboplatin (NSC 241240) has been cited by 82 publications

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Related Compound Libraries

Biological Activity

Description

Features

This product is not recommended to be dissolved in dimethylsulfoxide (DMSO).^[6]

Targets

DNA synthesis ^[1]
(A2780, SKOV-3, IGROV-1, HX62 cells)

In vitro

Carboplatin exhibits an inhibitory effect on cell proliferation in a human ovarian cancer cell line panel, including A2780, SKOV3, and IGROV-1 cells with IC50 of 6.1 μM, 12.4 μM and 2.2 μM, respectively. ^[1] Carboplatin also show the anti-proliferative activities in lung carcinoid cell line, such as UMC-11, H727, and H835 cells with IC50 of 36.4 μM, 3.4 μM and 35.8 μM, respectively. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Tca8113/ut	M1L0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUCyMVI26oDLzszN	M{P3RlczKGh?		M{PmW4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF\|N{GwOUc,OjZzM{exNFU9N2F-
Tca8113/CBP	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4eyOlIuOjYkgJpOwG0>	MVi3NkBp		MYDpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF\|N{GwOUc,OjZzM{exNFU9N2F-
Tca8113/PYM	NWj6TYNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWDYOGs{Oi1{NfMAje69VQ>?	MUW3NkBp		M{XGeIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF\|N{GwOUc,OjZzM{exNFU9N2F-
SKOV3	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\KWJE3OCCvZz;tcC=>	M3rjflEuPSCm		NWO5bVR2cW6qaXLpeJMh[2WubDD2bYFjcWyrdImgeIlu\SCmZYDlcoRmdnSueR?=	M1n4UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO3NFQ{Lz5{NkGzO\|A1OzxxYU6=
SKOV3	NInQOHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVmwMVQh\|rypL33s	NVPRWIVwOjRxNEivO\|IhcA>?		M1X6TIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl?	NIDSTlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGyOVI4Oyd-Mk[xNlUzPzN:L3G+
SKOV3	NV3DW3hxSXCxcITvd4l{KEG\|c3H5	NFHPepAzKM7:Zz;tcC=>	NYfmT2hiPDhiaB?=		Mnr1bY5lfWOnczDhdI9xfG:\|aYO=	M3XTNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUK1Nlc{Lz5{NkGyOVI4OzxxYU6=
OSA	NVXLW5hlS2yxbn;n[Y5q[yCDc4PhfS=>	NYfJfnFOOi53L{Wg{txO			NX7aU3d5emW\|dXz0d{BqdiCub4fldkBkd2yxbomg[o9zdWG2aX;uJIF{KGOxbYDhdoVlKHSxIHXpeIhmeiCETVmxJJNqWk6DIITy[YF1dWWwdB?=	M1T6d\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUGwOlIxLz5{NkGxNFYzODxxYU6=
A549	M1zDV2Z2[3Srb36gRZN{[Xl?	M2TYU\|AwOjVxNUCg{txO	M3LRdFI1KGh?		MWnkc5dvemWpdXzheIV{KG2rUj2yNFUh\XiycnXzd4lwdsLi	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlzN{OxO{c,OjV7MUezNVc9N2F-
H1975	MlS3SpVkfGmxbjDBd5NigQ>?	NGjQVYwxNzJ3L{WwJO69VQ>?	MWKyOEBp		MWHkc5dvemWpdXzheIV{KG2rUj2yNFUh\XiycnXzd4lwdsLi	NH\XOJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmxO\|MyPyd-MkW5NVc{OTd:L3G+
A549	NWnONYZ5TnWldHnvckBCe3OjeR?=	M4jiVlAwOjVxNUCg{txO	NUe1cY42OjRiaB?=		NUK1UIF3fXC{ZXf1cIF1\XNibXnSMVIyQCCneIDy[ZN{cW:w	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlzN{OxO{c,OjV7MUezNVc9N2F-
H1975	NYf1N3l5TnWldHnvckBCe3OjeR?=	NIXlSGoxNzJ3L{WwJO69VQ>?	NXOxTpJiOjRiaB?=		M2rBSpVxemWpdXzheIV{KG2rUj2yNVgh\XiycnXzd4lwdg>?	NFj2b4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmxO\|MyPyd-MkW5NVc{OTd:L3G+
A549	M17Bcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1PjNlI2KM7:TR?=	Mn60NlQhcA>?		NVP6dW06cW6qaXLpeJMh[2WubDDndo94fGh?	NFq2UnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmxO\|MyPyd-MkW5NVc{OTd:L3G+
H1975	NFvIfVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPweWg6OjVizszN	MmHDNlQhcA>?		MkPEbY5pcWKrdIOgZ4VtdCCpcn;3eIg>	NXfnfJl4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5NVc{OTdpPkK1PVE4OzF5PD;hQi=>
MDA-MB-231	Mme3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUmwMVIzOCEQvHevcYw>	M2\aZlczKGh?		NF3uUmtKSzVywrC9JFg3KM7:TR?=	NWPESIV5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|c3QTFpPkK1PFM4PjlzPD;hQi=>
T47D	NU\p[3dET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2H1XlAuOjJyIN88[{9udA>?	NEm5dnE4OiCq		M1vybWlEPTEEoE2gOFgvQSEQvF2=	NWPuUZpiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|c3QTFpPkK1PFM4PjlzPD;hQi=>
LCTCC	NXn2end{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV3iVZBNUUN3ME2zMljjiIoEtV2=	MoX4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5N{OxOlcoRjJ3N{ezNVY4RC:jPh?=
MCTCC	M{\j[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3rvbmlEPTB;Mj645qCKyrWP	NX\sWHl3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3O\|MyPjdpPkK1O\|c{OTZ5PD;hQi=>
MegTCC	NX7WRpk2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXXqfoZVUUN3ME20MlHjiIoEtV2=	NF7IXow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe3N\|E3Pyd-MkW3O\|MyPjd:L3G+
MonoTCC	NIPEN4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmH5TWM2OD13LkdihKnDvU1?	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd5M{G2O{c,OjV5N{OxOlc9N2F-
MCF7	M{DUUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYCyNEDPxE1?	MXm3NkBp		NEjYTVFqdmS3Y3XzJINmdGxiZHXheIghd2ZiSGCx{tIu\GWybHX0[YQhVUOINzDj[Yxtew>?	Mm\3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkmwNlUoRjJ3N{[5NFI2RC:jPh?=
A-549	MlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXqwMlUh\|ryP	MX6yOEBp	NITHZo5FVVORwrC=	NGX2RodqdmirYnn0d{Bk\WyuIHfyc5d1cCC\|aXfubYZq[2GwdHz5	NYixc3ZlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OVU3QTBpPkK1O\|U2PjlyPD;hQi=>
A-549	NGW4cVBCeG:ydH;zbZMhSXO\|YYm=	MlO4NE42KM7:TR?=	MVS0PEBp	NXTrSnBrTE2VT9Mg	Mnj0d4hwf3NiZXHycJkh[XCxcITvd4l{KG[nYYT1doV{KGmwY3z1[Ilv\yCkbHXiZolv\yCjbnSgZ4hzd22jdHnuJINwdmSnboPheIlwdg>?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd3NU[5NEc,OjV5NUW2PVA9N2F-
A-549	MX;GeYN1cW:wIFHzd4F6	NWD2SYlIOC53IN88US=>	MoXPOFghcA>?	MnjzSG1UV8Li	NWC0[pBte2ixd4OgZYJmenKjboSgcYlkem:2dXL1cIUh\Gm\|coXweIlwdg>?	MlO5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NUW2PVAoRjJ3N{W1OlkxRC:jPh?=
A-549	NYfSZ2ZmTnWldHnvckBCe3OjeR?=	NVu3XYlkOC53IN88US=>	NYfGeZAzPDhiaB?=	NGKyTYtFVVORwrC=	NVjJbXFicW6qaXLpeJMhd2ZiY3XscEBucWe{YYTpc47DqA>?	M{\KPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{W1OlkxLz5{NUe1OVY6ODxxYU6=
RMG-1	M1i5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTJ6LkigxtEhOy54IH3nM2w>	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd{NkmxN{c,OjV5Mk[5NVM9N2F-
FN-RMG-1	NFPmNWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\seoc3UUN3ME20NE42KMLzIESuNkBu\y:OCjFOwG0>	NFzHRno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUeyOlkyOyd-MkW3NlY6OTN:L3G+
RMG-1-hFUT	M1G2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV\ufXJ6UUN3ME21PE4yKMLzIEKuOEBu\y:O	M4X0VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{K2PVE{Lz5{NUeyOlkyOzxxYU6=
FN-RMG-1-hFUT	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYLJR\|UxRTFzOD64JOKyKDF\|LkigcYcwVA>?	MlrmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5Mk[5NVMoRjJ3N{K2PVE{RC:jPh?=
CHP-134	Ml\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFPYeWoyKM7:TR?=		MmX2SG1UV8Li	M4TON4lvcGmkaYTzJJNq\26rZnnjZY51KGOnbHyg[5Jwf3SqIHPvcYJqdmWmIIfpeIghT1ONMkizNFM4OQ>?	MoTRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NUi0OlMoRjJ3NkW4OFY{RC:jPh?=
IMR-32	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;OZVEh\|ryP		NWrGWVNRTE2VT9Mg	Ml\nbY5pcWKrdIOgd4lodmmoaXPhcpQh[2WubDDndo94fGhiY3;tZolv\WRid3n0bEBIW0t{OEOwN\|cy	NHv5Sm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1PFQ3Oyd-MkW2OVg1PjN:L3G+
CHP-134	Mn2ySpVkfGmxbjDBd5NigQ>?	NIrycpYyOCEQvF5CpC=>		NUj1WYVVTE2VT9Mg	NIjFdJlqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIghT1ONMkizNFM4OQ>?	NH7oe4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1PFQ3Oyd-MkW2OVg1PjN:L3G+
IMR-32	M2jqXWZ2[3Srb36gRZN{[Xl?	NXrVfItlOTBizszNxsA>		Ml;iSG1UV8Li	NE\sUm1qdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIghT1ONMkizNFM4OQ>?	NFHtWWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1PFQ3Oyd-MkW2OVg1PjN:L3G+
A549	NHjrPFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7FO5QxNjJvNECwNEDPxE1?	NFHubJc4OiCq		M3fLS2lEPTB;MUK2JOKyKDVwMDFOwG0>	NWSyR3l5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NlUzPDNpPkK1OlI2OjR\|PD;hQi=>
A549/CDDP	NEnnb29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYCwMlIuPDByMDFOwG0>	MlTDO\|IhcA>?		NYXTXXA3UUN3ME2yOFDDqMLzwrC0OU44KM7:TR?=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ{NUK0N{c,OjV4MkWyOFM9N2F-
H460	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1uxeVI1KGh?	NIDYUHRFVVOR	NGDPR\|FKSzVyPUeuPUDPxE1?	NXrCR\|Z7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1PVk6QTVpPkK1OVk6QTl3PD;hQi=>
H460	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPqO{46KM7:TR?=	NFqyOIozPCCq	NXj5bplHTE2VTx?=	MoDvd4hwf3NiYTDyZYRqd3OnboPpeIl7cW6pIHXm[oVkfCC2bzDYMZJigXN?	M3HIV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUm5PVk2Lz5{NUW5PVk6PTxxYU6=
NRK-52E	M4TzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2\HVlczyqCqwrC=		MofLTWM2OD1zMECgxtEhOTJwOTFOwG0>	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV4NU[wN{c,OjV3NkW2NFM9N2F-
RGE	M3XFcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MonWO\|LDqGkEoB?=		MlKxTWM2OD1{MjFCtUA4NjRizszN	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV4NU[wN{c,OjV3NkW2NFM9N2F-
NRK-52E	NEnSbVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnGxO\|LDqGkEoB?=		NXfLe2J{UUN6ME2xO\|khyrFiOT61JO69VQ>?	M4TSPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NU[1OlA{Lz5{NUW2OVYxOzxxYU6=
RGE	NXnheXM2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIrFT404OsLiaNMg		NEjqbpVKSzhyPU[zJOKyKDdwNDFOwG0>	NHzWZpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW2OVYxOyd-MkW1OlU3ODN:L3G+
SK-OV-3	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1z3[VczKGh?		NHnyUo9KSzVyPUGwOE45KM7:TR?=	M2DoNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUKwNVMzLz5{NUWyNFE{OjxxYU6=
ES-2	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3\vcVczKGh?		M4qwWGlEPTB;MUSuOkDPxE1?	MlPYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3MkCxN\|IoRjJ3NUKwNVMzRC:jPh?=
OVCAR-8	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1n6OlczKGh?		MUXJR\|UxRTl4LkCg{txO	NF7LT4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWyNFE{Oid-MkW1NlAyOzJ:L3G+
3AO	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnziO\|IhcA>?		MXnJR\|UxRTZ\|LkSg{txO	NH;M[Ig9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWyNFE{Oid-MkW1NlAyOzJ:L3G+
A2780	M1nMdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkLSO\|IhcA>?		NH7UT\|JKSzVyPUG0OU44KM7:TR?=	Ml63QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3MkCxN\|IoRjJ3NUKwNVMzRC:jPh?=
SW626	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHfQZ\|g4OiCq		NH;ze3hKSzVyPUm3MlAh\|ryP	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV{MEGzNkc,OjV3MkCxN\|I9N2F-
OVCAR-3	NFTjNlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUe3NkBp		MoDwTWM2OD1\|Mj62JO69VQ>?	Ml3DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3MkCxN\|IoRjJ3NUKwNVMzRC:jPh?=
A549	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYT0bFZiUUN3ME2xOVEvPTZiwsGgOVMvODZizszN	M1vmc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFYyLz5{NUK3O\|Q3OTxxYU6=
4T1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3zZ[GlEPTB;OESuOlIhyrFiM{CuNFUh\|ryPCjFOwG0>	MkP2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OlEoRjJ3Mke3OFYyRC:jPh?=
BALB/3T3	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTF2LkOwJOKyKDZwNkig{txO	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{S2NUc,OjV{N{e0OlE9N2F-
B16	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmG1TWM2OD14ND6zNEDDuSB4LkixJO69VQ>?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{S2NUc,OjV{N{e0OlE9N2F-
DU 145	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUDNVWw3UUN3ME2zOU4xPCEEsTCxO{42PCEQvF2=	M3joZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFYyLz5{NUK3O\|Q3OTxxYU6=
FaDu	Mn70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWD5XlhqUUN3ME20OU4{QSEEsTCxNU42OCEQvF2=	MmG1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OlEoRjJ3Mke3OFYyRC:jPh?=
HCV-29T	M1rFeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmXsTWM2OD12OD61O{DDuSB{Mj60PUDPxE1?	NYXSXZMxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|c1PjFpPkK1Nlc4PDZzPD;hQi=>
HL-60	NV7BWI9lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTFzLkGwJOKyKDRwNEeg{txO	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{S2NUc,OjV{N{e0OlE9N2F-
HT-29	M4XIXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NULxUJFZUUN3ME24PU4yPiEEsTCxPE45PiEQvF2=	NUHKcpc3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|c1PjFpPkK1Nlc4PDZzPD;hQi=>
H146	NH;YUHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M17jT2lEPTB;NEmuOuKyOTNwMTFOwG0>	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{NEK4Nkc,OjVzMkSyPFI9N2F-
H187	MmXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlXGTWM2OD1zMj63xtEzNjdizszN	MojJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkSyPFIoRjJ3MUK0NlgzRC:jPh?=
H128	NH7uWHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTFyNj60xtE6NjZizszN	MkOwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkSyPFIoRjJ3MUK0NlgzRC:jPh?=
H69	NXHaWHRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXOwcWxOUUN3ME23Ok46yrF{Nz64JO69VQ>?	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{NEK4Nkc,OjVzMkSyPFI9N2F-
H209	M{f2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfhc4VKSzVyPUK1PE4yyrF7OT64JO69VQ>?	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{NEK4Nkc,OjVzMkSyPFI9N2F-
DMS153	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3W4TGlEPTB;NUeuPOKyQS5{IN88US=>	NFfMN\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyOFI5Oid-MkWxNlQzQDJ:L3G+
H526	NEHiPGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1rtd2lEPTB;Nz6yxtEyNjdizszN	NX3p[4JWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlQzQDJpPkK1NVI1Ojh{PD;hQi=>
DMS114	NVjFZYVyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYq0NHhmUUN3ME24OU45yrFzMj64JO69VQ>?	MmrIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkSyPFIoRjJ3MUK0NlgzRC:jPh?=
DMS53	NHTKVm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVHDSZRKUUN3ME2xOFYvOsLzM{[uOEDPxE1?	MnPvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkSyPFIoRjJ3MUK0NlgzRC:jPh?=
HeLa	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXK1MVgxKM7:TR?=			MUXpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5	NInuXpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGwPVM3OCd-MkWxNFk{PjB:L3G+
MCF-7	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGS4[oo2NThyIN88US=>			M1PSO4lvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk>	NXTsUZhyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNFk{PjBpPkK1NVA6OzZyPD;hQi=>
MDA-MB-231	NUXS[FlQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2nje\|UuQDBizszN			M37KS4lvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk>	NIPvVnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGwPVM3OCd-MkWxNFk{PjB:L3G+
CaOV3	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Ml\HO\|IhcA>?		MWrJR\|UxRTh4LkGg{txO	MkTuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNki4OFkoRjJ3ME[4PFQ6RC:jPh?=
OVCAR-3	NEexcG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnPmO\|IhcA>?		MVvJR\|UxRTF5OT61JO69VQ>?	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4OEi0PUc,OjVyNki4OFk9N2F-
OVCAR-5	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVO3NkBp		NHW1R3ZKSzVyPUe1Mlch\|ryP	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4OEi0PUc,OjVyNki4OFk9N2F-
SKOV-3	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUG3NkBp		NEGxWZdKSzVyPUWwOEDPxE1?	NUnIfYN{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlg5PDlpPkK1NFY5QDR7PD;hQi=>
OVCAR-4	M1HHcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIfRcXY4OiCq		MlLKTWM2OD1{OUCuOkDPxE1?	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4OEi0PUc,OjVyNki4OFk9N2F-
OVCAR-8	M3TpSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYPPbIlxPzJiaB?=		NEDMVHdKSzVyPU[5NE4zKM7:TR?=	NH2wdpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2PFg1QSd-MkWwOlg5PDl:L3G+
MA148	NWL0VlEyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYiyOEBp		MUDJR\|UxRTh\|LkdihKnDueLCiUGuOEDPxGdxbXy=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh\|MUC5NUc,OjR6M{GwPVE9N2F-
A549	NFq1Z2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NF7iXYgzPCCq		MUXJR\|UxRTd5Nj6w5qCKyrIkgJmxMlkh\|rypL33s	NIW5WHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizNVA6OSd-MkS4N\|ExQTF:L3G+
MDA-MB-231	MkXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MUOyOEBp		M2nB[GlEPTB;N{S4MlDjiIoEsfMAjVEvOSEQvHevcYw>	NHntcWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizNVA6OSd-MkS4N\|ExQTF:L3G+
NCI-ADR/RES	MmrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3;tfVI1KGh?		MULJR\|UxRTF5NUOuNQKBkcLz4pEJOE41KM7:Zz;tcC=>	M2HleFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOxNFkyLz5{NEizNVA6OTxxYU6=
MA148	NEnSZYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYW0PEBp		M4S0RmlEPTB;MkiuNgKBkcLz4pEJNU4xKM7:Zz;tcC=>	MkPRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{GwPVEoRjJ2OEOxNFkyRC:jPh?=
A549	MnfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NIr2flU1QCCq		MlTXTWM2OD1zMUiuNQKBkcLz4pEJNU4zKM7:Zz;tcC=>	NETjXHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizNVA6OSd-MkS4N\|ExQTF:L3G+
MDA-MB-231	NUnTbHI4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2LFfVQ5KGh?		MXTJR\|UxRTF6Mz6w5qCKyrIkgJmxMlIhKM7:Zz;tcC=>	MoXKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{GwPVEoRjJ2OEOxNFkyRC:jPh?=
NCI-ADR/RES	M2Xt[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXjmfWJHPDhiaB?=		NGH3OVlKSzVyPUG5N{4x6oDLwsJihKkyNjlizsznM41t	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh\|MUC5NUc,OjR6M{GwPVE9N2F-
MA148	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWi3NkBp		NWfLU3NvUUN3ME2xN{446oDLwsJihKkyNjJizsznM41t	NE[xbGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizNVA6OSd-MkS4N\|ExQTF:L3G+
A549	MnuwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHra[HM4OiCq		Mn\oTWM2OD14ND6z5qCKyrIkgJmxMlEh\|rypL33s	NITmSlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizNVA6OSd-MkS4N\|ExQTF:L3G+
MDA-MB-231	M1HN[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUXNOHJ6PzJiaB?=		MkfFTWM2OD17OT615qCKyrIkgJmxMlEh\|rypL33s	M33SXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOxNFkyLz5{NEizNVA6OTxxYU6=
NCI-ADR/RES	NGH6PJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NI[5fYs4OiCq		NHHUc\|BKSzVyPUO3MlTjiIoEsfMAjVEvPyEQvHevcYw>	NVyzclZ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N\|ExQTFpPkK0PFMyODlzPD;hQi=>
A549	M2nHXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmTkO\|IhcA>?	MnKxSG1UVw>?	NEmwNpRKSzVyPUG1Nk41ODlizszN	NHHjcpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEeyNVMzOyd-MkS3NlE{OjN:L3G+
NCI-H157	MkjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mn7yO\|IhcA>?	Ml;YSG1UVw>?	MYfJR\|UxRTh7Lkm3O{DPxE1?	MkTTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5MkGzNlMoRjJ2N{KxN\|I{RC:jPh?=
PC9	Mm\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2fUWVczKGh?		MV7HR\|UxRTdzLkdCtVkvPSEEtV2=	NUixeXpSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NVg5ODlpPkK0OlE5QDB7PD;hQi=>
A549	NIrxZXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlHXO\|IhcA>?		M1SzeWdEPTB;MUO2xtE{OS54INM1UeKh	NIHsfXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[xPFgxQSd-MkS2NVg5ODl:L3G+
PC9	MV7BdI9xfG:\|aYOgRZN{[Xl?	M3jqS\|ExOCEEtV2=	M3T2SFczKGh?		M1TxRolv\HWlZYOgZZBweHSxc3nz	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZzOEiwPUc,OjR4MUi4NFk9N2F-
A549	NI\MPIpCeG:ydH;zbZMhSXO\|YYm=	NWLUTGZkOTByINM1US=>	MW[3NkBp		NGHLdJNqdmS3Y3XzJIFxd3C2b4Ppdy=>	MnPxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MUi4NFkoRjJ2NkG4PFA6RC:jPh?=
A549	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWHYNHBPOjRiaB?=		NHqySnNKSzFyPUGuOFc3KG6P	NVfacIkzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzPVY1OzdpPkK0N\|k3PDN5PD;hQi=>
H1299	NVLtNW5bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NF7D[mQzPCCq		MV;JR\|ExRTBwNESzJI5O	NXHudHZ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzPVY1OzdpPkK0N\|k3PDN5PD;hQi=>
HCC15	Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Ml\PNlQhcA>?		M1fGfWlEOTB;MD6zOFYhdk1?	M1TTOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{m2OFM4Lz5{NEO5OlQ{PzxxYU6=
H157	M4m5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2fDd\|I1KGh?		MYTJR\|ExRTBwOEGgcm0>	M3vQcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{m2OFM4Lz5{NEO5OlQ{PzxxYU6=
A2780	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmL2TWM2OD1zND6w5qCKyrIkgJmxMlQh\|ryP	NELWVYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKwPVY6Oyd-MkSyNFk3QTN:L3G+
A2780cisR	NEPPeG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoDpTWM2OD12OD655qCKyrIkgJmzMlkh\|ryP	M4\HRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkC5Olk{Lz5{NEKwPVY6OzxxYU6=
A2780ZD0473R	NVexco8zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF:zTodKSzVyPU[0MlbjiIoEsfMAjVMvOiEQvF2=	NFnYclA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKwPVY6Oyd-MkSyNFk3QTN:L3G+
SKOV-3	NIPpVlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4Llb2lEPTB;NEOuOQKBkcLz4pEJN{46KM7:TR?=	NFyzeok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKwPVY6Oyd-MkSyNFk3QTN:L3G+

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Western blot	pChK-2 / Chk-2 ; p-p53(S15) / p-p53(S46) / p-p53(S392) / p53 ; p-p38 / p38 / Cleaved PARP / PARP	30049957
Immunofluorescence	γH2AX	24348048
Growth inhibition assay	Cell viability	24348048

In vivo

In A2780 tumor xenografts, Carboplatin (60 mg/kg via i.p.) given as single agents shows a modest antitumor effect with the relative tumor volumes on day 6 of 8.4 compared to the control of 11.9, and the day 6 tumor weights relative to control (T/C) of 67%. ^[1] For the VC8 (Brca2-deficient) xenografts, Carboplatin treatment delays tumor growth and reduces tumor mass by 42% compared to the vehicle group. ^[3]

Protocol (from reference)

Cell Research:

^[1]

Cell lines: A2780, SKOV3, IGROV-1 and HX62
Concentrations: 0-200 μM
Incubation Time: 72 hours
Method:
3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assays: Exponentially growing A2780, SKOV3, IGROV-1 and HX62 ovarian cancer cells are plated in 96 well plates. A range of drug concentrations are added and the plates are incubated for 72 hours to allow for 3–4 doubling times. Each experiment is carried out in triplicate. Sulforhodamine B (SRB) assays: Exponentially growing A2780 cells are plated in 96 well microtitre plates. For experiments studying concomitant exposure, cells are exposed to increasing concentrations of both drugs for 96 hours. For experiments studying the effect of sequence of exposure to 17-AAG or carboplatin cells are exposed to increasing concentrations of 17-AAG or carboplatin for 24 hours. A period of 24-hour exposure to the first agent is chosen so that the A2780 cells would be exposed to the first drug for at least one doubling time (18-24 hours). The cells are then washed with sterile phosphate buffered saline and the medium is replenished. Following this, the second drug (to which the cells are not exposed to in the first 24 hours) or medium is added for 96 hours. All experiments are carried out in triplicate. The results of combination studies are analyzed using the well-established principles of median effect analysis method. The effects of the combination are calculated using an in-house spreadsheet.
(Only for Reference)

Animal Research:

^[1]

Animal Models: The A2780 human ovarian cancer cell line is grown as a subcutaneous xenograft in female athymic NCr nude mice (nu/nu) in each flank.
Dosages: ≤60 mg/kg (When Carboplatin is dissolved in sodium chloride solution, it will induce physio-chemical and pharmacokinetic changes.)
Administration: Administered via i.p.
(Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	Water	14 mg/mL warmed (37.71 mM)
	DMSO	Insoluble
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight	371.25
Formula	C₆H₁₂N₂O₄Pt
CAS No.	41575-94-4
Storage	2 years 4°C(in the dark) powder
Smiles	C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]

Download Carboplatin (NSC 241240) SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Dilution Calculator Molecular Weight Calculator

Clinical Trial Information

NCT Number	Recruitment	Interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05181462	Not yet recruiting	Drug: Carboplatin\|Drug: Gemcitabine\|Drug: Nadunolimab	Triple Negative Breast Cancer	Cantargia AB\|Spanish Breast Cancer Research Group	January 2022	Phase 1\|Phase 2
NCT04907968	Recruiting	Drug: XMT-1536 (Upifitamab Rilsodotin)\|Drug: Carboplatin	Platinum-sensitive Ovarian Cancer (UPGRADE-A)	Mersana Therapeutics\|IQVIA Biotech	June 11 2021	Phase 1\|Phase 2
NCT04606914	Recruiting	Drug: mirvetuximab soravtansine (MIRV; IMGN853)	Ovarian Cancer\|Fallopian Tube\|Primary Peritoneal Cancer	University of Alabama at Birmingham	May 27 2021	Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Frequently Asked Questions

Question 1:
Can you advise what solvent to use and the concentration for S1215 for in vitro use?

Answer:
DMSO will affact the activity of platinum agents. For in vitro use, according to our experience in dissolving this compound, we didn't find any solvent can dissolve it alone, but S1215 can be dissolved in co-solvent ethanol:water=1:2 at 15 mg/ml. We didn't test the stablility of the drug in such vehicle, so it is recommended to prepare the solution just before use.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):